These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31395602)

  • 1. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
    Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
    Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
    He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
    Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
    Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
    Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
    Albouhair S; Morgado E; Lavau C
    PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
    Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
    Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Schneider P; de Lorenzo P; Valsecchi MG; den Boer ML; Pieters R
    Blood; 2007 Oct; 110(7):2774-5. PubMed ID: 17881645
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
    de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
    EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
    Richter WF; Shah RN; Ruthenburg AJ
    Elife; 2021 Jul; 10():. PubMed ID: 34263728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Schneider P; Nollau P; Horstmann M; Beverloo HB; van der Voort E; Valsecchi MG; de Lorenzo P; Sallan SE; Armstrong SA; Pieters R
    Blood; 2005 Oct; 106(7):2484-90. PubMed ID: 15956279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.
    Català A; Pastor-Anglada M; Caviedes-Cárdenas L; Malatesta R; Rives S; Vega-García N; Camós M; Fernández-Calotti P
    Oncotarget; 2016 Aug; 7(31):49786-49799. PubMed ID: 27391351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
    Armstrong SA; Kung AL; Mabon ME; Silverman LB; Stam RW; Den Boer ML; Pieters R; Kersey JH; Sallan SE; Fletcher JA; Golub TR; Griffin JD; Korsmeyer SJ
    Cancer Cell; 2003 Feb; 3(2):173-83. PubMed ID: 12620411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Schneider P; Meier M; Beverloo HB; Pieters R
    Haematologica; 2007 Nov; 92(11):1565-8. PubMed ID: 18024407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
    Brown P; Levis M; McIntyre E; Griesemer M; Small D
    Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.
    Chillón MC; Gómez-Casares MT; López-Jorge CE; Rodriguez-Medina C; Molines A; Sarasquete ME; Alcoceba M; Miguel JD; Bueno C; Montes R; Ramos F; Rodríguez JN; Giraldo P; Ramírez M; García-Delgado R; Fuster JL; González-Díaz M; Menendez P
    Leukemia; 2012 Nov; 26(11):2360-6. PubMed ID: 22705992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
    Brown P; Levis M; Shurtleff S; Campana D; Downing J; Small D
    Blood; 2005 Jan; 105(2):812-20. PubMed ID: 15374878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia.
    Sahoo BK; Lin YC; Tu CF; Lin CC; Liao WJ; Li FA; Li LH; Mou KY; Roffler SR; Wang SP; Yeh CT; Yao CY; Hou HA; Chou WC; Tien HF; Yang RB
    Haematologica; 2023 May; 108(5):1284-1299. PubMed ID: 36005562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsed infant MLL-rearranged acute lymphoblastic leukemia with additional genetic alterations.
    Ishida H; Kanamitsu K; Washio K; Muraoka M; Sakakibara K; Matsubara T; Kanzaki H; Shimada A
    Pediatr Blood Cancer; 2016 Nov; 63(11):2059-60. PubMed ID: 27322816
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.